Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

October 13, 2026 updated by: Vertex Pharmaceuticals Incorporated

A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581 in healthy participants and in participants with CF. VX-581 will be administered alone and in combination with TEZ and D-IVA. The study consists of Screening Phase, Run-In Phase (CF only), Treatment Phase and Safety Follow-up Phase.

Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Study Type

Interventional

Enrollment (Estimated)

152

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Kansas
      • Overland Park, Kansas, United States, 66212
        • Recruiting
        • Altasciences - Kansas City

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Parts A, B, C:

    • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
    • A total body weight of more than (>) 50 kg
  • Part D:

    • Confirmed diagnosis of CF

Key Exclusion Criteria:

  • Parts A, B, C:

    • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
    • Any condition possibly affecting drug absorption
  • Part D:

    • History of clinically significant cirrhosis with or without portal hypertension.

Other protocol defined Inclusion/Exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A: Single Ascending Dose

Participants will be randomized to receive a single dose of VX-581.

Suspension for Oral Administration.

Tablets for Oral Administration.

Placebo Comparator: Placebo: Part A

Participants will be randomized to receive a single dose of placebo matched to VX-581.

Suspension for Oral Administration.

Experimental: Part B: Multiple Ascending Dose

Participants will be randomized to receive multiple doses of VX-581.

Suspension for Oral Administration.

Tablets for Oral Administration.

Placebo Comparator: Placebo: Part B

Participants will be randomized to receive multiple doses of placebo matched to VX-581.

Suspension for Oral Administration.

Experimental: Part C: VX-581 with TEZ/D-IVA or D-IVA

Participants will be randomized to receive multiple doses VX-581 in combination with TEZ/D-IVA or D-IVA.

Suspension for Oral Administration.

Tablets for Oral Administration.

Tablet for Oral Administration.

Other Names:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

Other Names:
  • VX-661
  • tezacaftor
Placebo Comparator: Placebo: Part C

Participants will be randomized to receive placebo matched to VX-581 in combination with TEZ/D-IVA or D-IVA.

Suspension for Oral Administration.

Tablet for Oral Administration.

Other Names:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

Other Names:
  • VX-661
  • tezacaftor
Experimental: Part D: VX-581 with TEZ/D-IVA or D-IVA in CF

Participants with CF will enter a run-in period and receive ELX/TEZ/IVA. Following the run-in period participants will receive VX-581 in combination with TEZ/D-IVA or D-IVA in the treatment period. Following the treatment period, participants will enter a 14-day Washout Period and receive ELX/TEZ/IVA. (Part D will be open-label)

Suspension for Oral Administration.

Tablets for Oral Administration.

Tablet for Oral Administration.

Other Names:
  • VX-561
  • deutivacaftor

Tablet for Oral Administration.

Other Names:
  • VX-661
  • tezacaftor

Fixed dose combination (FDC) Tablets for Oral Administration.

Other Names:
  • VX-445/VX-661/VX-770
  • elexacaftor/tezacaftor/ivacaftor

Tablet for Oral Administration.

Other Names:
  • VX-770
  • Ivacaftor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Day -1 up to Day 8
From Day -1 up to Day 8
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Day -1 up to Day 17
From Day -1 up to Day 17
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Day -1 up to Day 17
From Day -1 up to Day 17
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From Signing of Informed Consent up to Day 105
From Signing of Informed Consent up to Day 105

Secondary Outcome Measures

Outcome Measure
Time Frame
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581
Time Frame: On Day 1
On Day 1
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) Post-Dose of VX-581
Time Frame: On Day 1
On Day 1
Part B: Cmax of VX-581
Time Frame: On Days 1, 7, and 10
On Days 1, 7, and 10
Part B: AUC0-24h Post-Dose of VX-581
Time Frame: On Days 1, 7, and 10
On Days 1, 7, and 10
Part C: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time Frame: On Days 1, 7, and 10
On Days 1, 7, and 10
Part C: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time Frame: On Days 1, 7, and 10
On Days 1, 7, and 10
Part D: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time Frame: On Day 1 and Day 28
On Day 1 and Day 28
Part D: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Time Frame: On Day 1 and Day 28
On Day 1 and Day 28
Part D: Absolute Change in Sweat Chloride (SwCl)
Time Frame: From Baseline Up To Day 28
From Baseline Up To Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 9, 2025

Primary Completion (Estimated)

July 12, 2027

Study Completion (Estimated)

July 12, 2027

Study Registration Dates

First Submitted

December 4, 2025

First Submitted That Met QC Criteria

December 4, 2025

First Posted (Actual)

December 16, 2025

Study Record Updates

Last Update Posted (Actual)

October 19, 2026

Last Update Submitted That Met QC Criteria

October 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • VX25-581-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.